BioSpace News Archive

Valo Therapeutics Oy announces that it has secured funding of approximately EUR 2.23 million from the European Innovation Council for a project to progress the company’s innovative PeptiCHIP technology.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced monotherapy Phase I dose escalation results of the ongoing Phase I/II trial of BT8009, a novel BTC™ targeting Nectin-4.

Actinium Pharmaceuticals, Inc. today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19, 2023 at the World Center Marriott in Orlando, Florida.

Endomimetics announced a collaboration with BISCO, Inc., to support development of a dental application for the Endomimetics’ Bionanomatrix™ technology.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, March 1, 2023, to provide a corporate update and discuss details of the Company’s financial results for the quarter and year ended December 31, 2022.

NANO-X IMAGING LTD, an innovative medical imaging technology company announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI, has connected to the Nuance Precision Imaging Network™.

Royal Biologics, a company specializing in Advanced Cellular Technologies & Enhanced Autologous Solutions, today announces the commercial launch of BIOINCYTE™ PRFM, a next-generation Platelet Rich Plasma (PRP) system.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company will deliver several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center.

Delix Therapeutics (the “Company”), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced its collaboration with two partners that will help expedite the company’s drug development pipeline.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the appointments of two pharmaceutical industry veterans to its executive leadership team.